Ropivacaine and Abametapir: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jun 30, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Abametapir
No brand names on recordRopivacaine
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Abametapir is a lotion used to treat head lice. Even though you rub it on your scalp, a little gets into your body and can slow down a liver enzyme called CYP1A2. That same enzyme helps break down ropivacaine, a local anesthetic (numbing medicine). If the enzyme is slowed, ropivacaine can build up higher than expected, which could raise the chance of side effects.
The good news is this is a predicted (theoretical) concern, and your care team can plan around it easily. If you have used abametapir recently, just let your pharmacist or doctor know before you get any procedure that uses ropivacaine.
Mechanism: Abametapir inhibits CYP1A2. Ropivacaine is metabolized partly via CYP1A2 (to 3-hydroxyropivacaine), so inhibition is predicted to increase ropivacaine exposure (higher AUC/Cmax), raising the risk of dose-related toxicity (CNS and cardiovascular effects). Neither agent is a prodrug, so effect is increased, not reduced.
- Direction: increased ropivacaine exposure
- Severity/Evidence: major, theoretical
- Onset: unspecified; inhibition may persist for up to 2 weeks after topical application
- Management: Avoid CYP1A2 substrates for 2 weeks after abametapir application; if unavoidable, avoid abametapir. If co-use occurs, consider dose individualization and closer monitoring for toxicity.
What happens
Increased exposure of CYP1A2 substrates
Interaction Deep Dive
Within a two-week window following abametapir administration, CYP1A2 substrates should not be used. When that avoidance cannot be achieved, abametapir itself should be avoided instead 1.
Why it happens (mechanism)
Inhibition of CYP1A2-mediated metabolism by abametapir
How to manage this interaction
What the care team typically does:
- Separate the two in time. The label advises avoiding CYP1A2 substrates like ropivacaine for 2 weeks after abametapir is applied.
- If that timing is not feasible, the alternative is to avoid using abametapir.
- If both are truly needed together, the ropivacaine dose may be adjusted and individualized by your care team, and they may monitor you more closely for side effects.
What you should do: Keep taking or using everything as prescribed, and tell your pharmacist or prescriber if you have used abametapir recently, especially before any procedure or surgery that involves a numbing medicine.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Ropivacaine and Abametapir together?
Abametapir can slow the breakdown of ropivacaine and raise its levels, so tell your care team if you have used abametapir in the past 2 weeks before getting ropivacaine; they can adjust timing, dosing, or monitoring. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Ropivacaine and Abametapir interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Ropivacaine and Abametapir interaction managed?
What the care team typically does: Separate the two in time. The label advises avoiding CYP1A2 substrates like ropivacaine for 2 weeks after abametapir is applied. If that timing is not feasible, the alternative is to avoid using abametapir. If both are truly needed together, the ropivacaine dose may be adjusted and individualized by your care team, and they may monitor you more closely for side e… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Ropivacaine or Abametapir need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: XEGLYZE(TM) topical lotion, abametapir topical lotion. Dr Reddy’s Laboratories Inc (per FDA), Princeton, NJ, 2020. DailyMed
Keep reading about Abametapir
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist